Clinical Trials Browser

Phase 1/2 × OTHER × lanreotide × Clear all

NCT05048901 2026-04-09

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT03043664 2023-06-29

PLANET

Phase 1/2 Completed

22 enrolled 12 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor